27.14
price down icon1.27%   -0.3558
 
loading
전일 마감가:
$27.50
열려 있는:
$27.59
하루 거래량:
72,387
Relative Volume:
0.14
시가총액:
$1.58B
수익:
$1.23M
순이익/손실:
$-185.98M
주가수익비율:
-
EPS:
-
순현금흐름:
$-156.42M
1주 성능:
-13.18%
1개월 성능:
-16.28%
6개월 성능:
-24.77%
1년 성능:
+0.00%
1일 변동 폭
Value
$26.76
$29.09
1주일 범위
Value
$25.74
$31.35
52주 변동 폭
Value
$10.42
$47.97

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name
명칭
Spyre Therapeutics Inc
Name
전화
(617) 651-5940
Name
주소
221 CRESCENT STREET, WALTHAM
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
SYRE's Discussions on Twitter

SYRE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
SYRE 27.16 1.58B 1.23M -185.98M -156.42M 0.00
VRTX 448.13 115.74B 10.63B -479.80M -1.35B 13.33
REGN 742.33 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.04 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.38 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.62 24.49B 3.30B -501.07M 1.03B 11.54

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-12-20 개시 BTIG Research Buy
2023-12-11 개시 Guggenheim Buy
2023-12-11 개시 Jefferies Buy
2020-05-04 개시 Piper Sandler Overweight
2019-03-21 개시 JP Morgan Overweight
2018-09-04 다운그레이드 Wells Fargo Outperform → Market Perform
2018-04-24 개시 Evercore ISI Outperform
2018-03-14 재확인 Needham Buy
모두보기

Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스

pulisher
Nov 20, 2024

First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq

Nov 20, 2024
pulisher
Nov 20, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire

Nov 20, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz

Nov 19, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics revises net loss per share calculations - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics launches $200 million public offering - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

SYRE Crosses Below Key Moving Average Level - Nasdaq

Nov 14, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre reports promising Phase 1 results for IBD therapy - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre's IBD Drug Shows Breakthrough 90-Day Half-Life in Phase 1 Trial, 4x Better Than Standard | SYRE Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $46.43 Average PT from Brokerages - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Spyre Therapeutics to Reveal Key IBD Drug Trial Data: SPY001 Results Coming Nov 12 | SYRE Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Q1 Earnings Estimate for SYRE Issued By Wedbush - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 09, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analysts - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics: Q3 Earnings Snapshot - Thehour.com

Nov 08, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics Advances IBD Treatment Pipeline - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Nov 07, 2024
pulisher
Nov 03, 2024

292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire

Nov 01, 2024
pulisher
Oct 30, 2024

Spyre Therapeutics to Participate in Upcoming November Investor Conferences - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics director sells shares worth $10,929 - Investing.com India

Oct 29, 2024
pulisher
Oct 28, 2024

Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Jeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Spyre Therapeutics' Catalyst Cascade On Track For Late 2024 - RTTNews

Oct 26, 2024
pulisher
Oct 25, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap UpHere's Why - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Assenagon Asset Management S.A. Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Oct 25, 2024
pulisher
Oct 18, 2024

SPY-003, an extended half-life MAb with twice-a-year projected human maintenance dosing - BioWorld Online

Oct 18, 2024
pulisher
Oct 18, 2024

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $43.43 - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.5%Time to Buy? - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Results from Spyre Therapeutics Inc. (SYRE) show potential - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Wedbush’s latest rating for SYRE stock - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

SYRE’s 2023 Market Dance: Up 42.47% – Time to Invest? - The InvestChronicle

Oct 15, 2024
pulisher
Oct 15, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $43.43 Consensus PT from Analysts - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Spyre Therapeutics Advances SPY003 for IBD Treatment - TipRanks

Oct 15, 2024
pulisher
Oct 14, 2024

Spyre shares rise on positive SPY003 data, analyst maintains Buy By Investing.com - Investing.com UK

Oct 14, 2024

Spyre Therapeutics Inc (SYRE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):